We are live on ! Find out more
FCMI

Foresite Capital Management I Portfolio holdings

AUM $21.4M
1-Year Est. Return 80.48%
This Fund
S&P 500
This Quarter Est. Return
+26.25%
1 Year Est. Return
-80.48%
3 Year Est. Return
-40.72%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$23.1M
Cap. Flow
-$39.1M
Cap. Flow %
-32.74%
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.17M

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$22.4M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$6.46M
3
NVAX icon
Novavax
NVAX
+$6.05M
4
TLPH icon
Talphera
TLPH
+$5.33M
5
XNCR icon
Xencor
XNCR
+$26.5K

Sector Composition

Rank Sector Weight
1 Healthcare 87.95%
2 Miscellaneous 12.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
1
Karyopharm Therapeutics
KPTI
$40.6M
$64.1M 53.75%
91,827
-13,889
-13% -$6.46M
AMBI
2
DELISTED
Ambit Biosciences Corp
AMBI
$14.4M 12.05%
2,079,569
– –
XNCR icon
3
Xencor
XNCR
$1.98B
$9.5M 7.96%
817,300
-2,700
-0.3% -$26.5K
TLPH icon
4
Talphera
TLPH
$62.3M
$8.69M 7.29%
42,399
-26,555
-39% -$5.33M
BDSI
5
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$8.45M 7.08%
700,000
– –
OREX
6
DELISTED
Orexigen Therapeutics, Inc.
OREX
$7.72M 6.48%
125,000
– –
RXDX
7
DELISTED
Ignyta, Inc.
RXDX
$4.54M 3.81%
500,000
– –
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$1.89M 1.59%
55,767
+34,875
+167% +$1.17M
NVAX icon
9
Novavax
NVAX
$1.69B
– –
-66,810
Closed -$6.05M
NVAX icon
10
PUT
Novavax
NVAX
$1.69B
– –
-100
Closed -$906K
KERX
11
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-1,312,006
Closed -$22.4M

Similar funds

A
Atlassian San Francisco, California $21M AUM 71.86% 1-Year Est. Return
CVGI
Craft Ventures GP II San Francisco, California $24.1M AUM 83.06% 1-Year Est. Return
AEPI
AH Equity Partners IV Menlo Park, California $24.5M AUM 73.4% 1-Year Est. Return
AGDR
AdamCapital Gestao de Recursos Rio De Janeiro, Brazil $18.1M AUM 32.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
WL
WiL LLC Palo Alto, California $17.5M AUM 75.04% 1-Year Est. Return
NVPX
Norwest Venture Partners XIII Palo Alto, California $25.8M AUM 76.52% 1-Year Est. Return
SVGI
Sozo Ventures GP I Redwood City, California $16.3M AUM 66.18% 1-Year Est. Return

Foresite Capital Management I's Q2 2014 Portfolio in Review

As of Q2 2014, Foresite Capital Management I held 11 positions worth $119M, down 16% from $142M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management I withdrew a net $39.1M in Q2 2014, closing 3 positions and reducing 3 holdings. Its most notable exit was Keryx Biopharmaceuticals Inc, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Miscellaneous.

Against the trend, Foresite Capital Management I added an estimated $1.17M to Acceleron Pharma.

  • Foresite Capital Management I added most to Acceleron Pharma in Q2 2014, an estimated $1.17M increase.
  • Foresite Capital Management I's biggest Q2 2014 reduction was Karyopharm Therapeutics, cutting an estimated $6.46M.
  • Foresite Capital Management I fully exited Keryx Biopharmaceuticals Inc in Q2 2014, selling an estimated $22.4M.
  • Foresite Capital Management I's ten largest holdings make up 100% of its $119M portfolio in Q2 2014.
  • Foresite Capital Management I opened 0 new positions and closed 3 in Q2 2014.
  • Foresite Capital Management I's portfolio value fell 16% quarter-over-quarter to $119M.

Based on Foresite Capital Management I's 13F filing for Q2 2014, filed 11 Aug 2014.